Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBIT Margin (2016 - 2025)

Amicus Therapeutics filings provide 14 years of EBIT Margin readings, the most recent being 8.61% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 206.0% to 8.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.17%, a 46.0% increase, with the full-year FY2025 number at 5.17%, up 46.0% from a year prior.
  • EBIT Margin hit 8.61% in Q4 2025 for Amicus Therapeutics, down from 20.27% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 20.27% in Q3 2025 to a low of 95.71% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 22.53% (2023), compared with a mean of 29.28%.
  • Biggest five-year swings in EBIT Margin: crashed -2492bps in 2022 and later soared 5512bps in 2023.
  • Amicus Therapeutics' EBIT Margin stood at 87.82% in 2021, then skyrocketed by 45bps to 48.05% in 2022, then surged by 93bps to 3.21% in 2023, then surged by 433bps to 10.67% in 2024, then dropped by -19bps to 8.61% in 2025.
  • The last three reported values for EBIT Margin were 8.61% (Q4 2025), 20.27% (Q3 2025), and 6.12% (Q2 2025) per Business Quant data.